Printer Friendly

OPTICALLY ACTIVE COMPOUNDS CATALYZE PHARMACEUTICAL GROWTH, ACCORDING TO TECHNOLOGY CATALYSTS

     OPTICALLY ACTIVE COMPOUNDS CATALYZE PHARMACEUTICAL GROWTH,
                  ACCORDING TO TECHNOLOGY CATALYSTS
    FALLS CHURCH, Va., Nov. 18 /PRNewswire/ -- Technology Catalysts International Corporation issued the following:
    Optically Active Compounds are the most heavily invested and researched aspect of pharmaceutical product development.  The present world market for optically pure drugs is conservatively estimated to be $18 billion, measured at the ex-factory pharmaceutical shipment level.  By the year 2000, the market value is minimally expected to increase to $40 billion, equivalent to an average annual growth rate of 9.3 percent.  At the bulk active shipment level, the corresponding values for 1991 and 2000 are $3 billion and $6 billion on a global basis.  The factors which are driving the research and support these expectations are:
    -- Increased awareness that only one stereoisomer or chiral form has a greater patient benefits:cost ratio than the racemic mixture.
    -- Flurry of use patents filed worldwide on one isomer of established major racemic drugs.
    -- Regulatory agencies worldwide have published policies, guidelines or statements which are interpreted differently in practice, leading to faster commercialization of "racemic switches," such as S-(+)-ibuprofen, S-(+)-atenolol and S-(+)-terfenadine.
    -- Pharmaceutical companies are employing five strategies to protect branded optically pure drugs and racemates and sustain growth after patent expiration:
       -- Develop new dosage forms of optically pure drugs such as
          diltiazem and naproxen.
       -- Create optically pure forms of branded racemates going off
          patent (racemic switches).
       -- Test new dosage forms of racemic switches such as
          S-(+)-ibuprofen.
       -- Use low-cost asymmetric syntheses, biotransformations or
          prep HPLC to inexpensively manufacture optically pure drugs
          at a higher level of purity to protect against generic
          competition.
       -- Employ Rx to OTC switches of optically pure drugs such as
          naproxen, S-(+)-terfenadine and S-(+)-ibuprofen.
    -- Expanded number of Initial Public Offerings (IPOs, such as Celgene and Sepracor) and several acquisitions which have resulted from the information published in "Optically Active Chemical Compounds, Vol. I," in 1990.
    In its new report on "Optically Active Chemical Compounds, Vol. II," Technology Catalysts estimates that about $40 billion of presently marketed racemates could be switched to their optically pure form for the purpose of extending/obtaining new patent protection and new therapeutic indications.  While not all racemates will be switched, there is overwhelming evidence of current development programs at over 100 multinational pharmaceutical companies to support the growth expectations cited in the study.  For example, Technology Catalysts identified 106 racemates being developed in topical, transdermal and/or transmucosal optically pure dosage forms.  Of the 12 therapeutic classes identified, 57 percent were in cardiovascular, CNS and hormonal products.
    The purpose of the report is to stimulate global strategic alliances and collaborative R&D to solve the problems of chronic diseases, especially immunological disorders, arthritis, cardiovascular and CNS.  The report also reviews aspects of international regulations, discusses patent issues in chiral compounds and provides:
    -- Commercial intelligence on 108 companies in North American, Japan and Europe.
    -- Information on 20 companies which are acquisition candidates.
    -- Over 60 specific business and licensing opportunities which are available for companies seeking to acquire technology.
    -0-                   11/18/91
    /NOTE:  Sections of the report are available./
    /CONTACT:  Paul Weitz of Technology Catalysts, 703-237-9600/ CO:  Technology Catalysts International Corporation ST:  Virginia IN:  CHM SU:  PDT MH-TW -- DC030 -- 4609 11/18/91 16:21 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 18, 1991
Words:540
Previous Article:FEDERAL EXPRESS ANNOUNCES PROMOTIONS
Next Article:PHARMAKINETICS LABORATORIES, INC., RELEASES FIRST QUARTER RESULTS
Topics:


Related Articles
ALTUS BIOLOGICS RECEIVES NIH GRANT TO EXPAND NOVEL CLEC(TM) TECHNOLOGY USEFUL IN INDUSTRIAL PROCESSES
NEWBIOTICS/ELAN TO DEVELOP COLON CANCER TREATMENT.
$11 Million Financing for NewBiotics Inc.
VioQuest Pharmaceuticals Subsidiary Chiral Quest, Inc., Announces Ligand Technology Relationship With Pfizer, Inc.
Rib-X, Novel Antibiotic Discovery Firm, Launches First Clinical Trial From Ribosome-Based Technology Platform.
Bentley Pharmaceuticals Named to Deloitte's 2006 Technology Fast 500 for the Second Year in a Row.
Two synthetic steps: exploring new chemical reactivities for highly efficient synthesis towards green chemistry.
Catalyst Pharmaceutical Partners Licenses Exclusive Rights to New Class of GABA Aminotransferase Inhibitors From Northwestern University.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters